Rezolute, Inc. Common Stock (NV)
$3.84
-$0.11 (-2.78%)
$3.67Day Range$3.95
Key Statistics
Market Cap
$369.76M
Shares Outstanding
96.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 23, 2011
Round Lot
100
Locale
US
Trading Data
Day Open
$3.95
Day High
$3.95
Day Low
$3.67
Volume
2.53M
VWAP
$3.81
Prev Close
$3.95
Transactions
--
Acc. Volume
--
About Rezolute, Inc. Common Stock (NV)
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
PHARMACEUTICAL PREPARATIONSSIC 283471 employees275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065650-206-4507IPO Dec 23, 2011US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001509261
- Composite FIGI
- BBG001XWWHL4
- Share Class FIGI
- BBG001XWWJC0
- Ticker Root
- RZLT
- SIC Code
- 2834
About Rezolute, Inc. Common Stock (NV) (RZLT) Stock
Rezolute, Inc. Common Stock (NV) (RZLT) closed the 2026-09-18 session at $3.84, down 2.78% versus the previous close (-0.11). The stock opened at $3.95 and traded between $3.67 and $3.95 during that session. Session trading volume was 2.5M shares. The volume-weighted average price (VWAP) is $3.81.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Rezolute, Inc. Common Stock (NV) has a market capitalization of $369.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RZLT is listed on the XNAS exchange. The company employs approximately 71 people. Rezolute, Inc. Common Stock (NV) is headquartered in REDWOOD CITY, CA. The recorded listing date is 2011-12-23.
On this page you can find market RZLT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.